Efficacy of subconjunctival bevacizumab injection in corneal neovascularisation.
Artículo
en Inglés
| IMSEAR
| ID: sea-134488
ABSTRACT
Aim:
To evaluate the therapeutic effect of subconjunctival Bevacizumabon corneal neovascularisationDesign:
A prospective randomized noncomparative study.Method:
The charts of 10 consecutive patients with corneal neovascularisation who received single S.C. inj. of Bevacizumab (2.5mg/0.1ml) were reviewed. Digital photographs of the cornea were taken pre & post injection & then at 1 wk,3wk & 2months duration. Digital photographs of the cornea were analyzed to determine the length, density, extent, centricity of corneal neovascularisation and the area of cornea covered by neovascularisation as a percentage of the total corneal area.Results:
Subconjunctival injection of Bevacizumab (Avastin) caused significant regression of corneal neovascularisation in 1 pt, partial regression in 6 pts and no effect in 3 pts as measured by length and surface area of neovascularisation. No significant ocular or systemic complications were found.Conclusion:
Subconjunctival inj. of Bevacizumab is effective in regressing corneal neovascularisation.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Glutamato de Sodio
/
Humanos
/
Conjuntivitis Hemorrágica Aguda
/
Neovascularización de la Córnea
/
Inyecciones Intraoculares
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Ensayo Clínico Controlado
Idioma:
Inglés
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS